Clik here to view.
2013 was a record breaking year for orphan drugs
By Kurt R. Karst – Since we started this blogging gig seven years ago (March 6th was our anniversary) we’ve strived to cover topics of interest to FDA-regulated companies, fellow food and drug...
View ArticleClik here to view.
Orphan drug developer Infant Bacterial Therapeutics gets $4.1 million
Sweden-based BioGaia is pumping another $4.1 million into its subsidiary Infant Bacterial Therapeutics, which is developing an orphan drug focused on an intestinal disease specific to premature babies....
View ArticleClik here to view.
Morning Read: Is Martin Shkreli pharma’s version of the patent troll?
TOP STORIES Martin Shkreli and Turing Pharmaceuticals are getting the backlash they deserve – in the form of backhands across the face by the likes of John Carroll, as well as in-depth examinations by...
View ArticleClik here to view.
Why drug-price regulation’s time has come
I’m a proponent of free markets and in general defend drug companies in their price setting, especially when they’re introducing new, innovative products with real clinical and financial benefits....
View ArticleClik here to view.
A new way to treat chronic cough got a big round of funding to move faster...
Patara Pharma, an orphan drug startup, will use a $26 million investment to accelerate testing of its treatment for chronic cough and systemic mastocytosis. Patara’s drug candidate has already passed...
View ArticleClik here to view.
Report: Orphan drugs cost 13.8 percent more per patient
Orphan drugs cost 13.8 times more per patient than mass-market drugs – a somewhat static fact that continues to impact the course of biopharma R&D. Meaning: There’s been little change in the past...
View ArticleClik here to view.
Orphan Drug Act’s role as an incentive to develop rare disease treatments
How can policymakers incentivize innovators to invest in new treatments for rare diseases? One solution policymakers invoked was enacting the Orphan Drug Act of 1983 which provided a number of...
View ArticleClik here to view.
Pharma companies routinely bend orphan drug rules
A Kaiser Health News investigation shows that the system intended to help desperate patients is being manipulated by drugmakers to maximize profits and to protect niche markets for medicines already...
View ArticleClik here to view.
Grassley opens probe into Orphan Drug Act abuses
In a statement, Grassley said the inquiry is “based on reporting from Kaiser Health News” and strong consumer concern about high drug prices.
View ArticleClik here to view.
Are pharma industry companies converting patients with orphan diseases into...
Behind-the-scenes partnerships between the pharmaceutical industry and advocacy groups may work against lowering the cost of high-priced drugs.
View Article2013 was a record breaking year for orphan drugs
By Kurt R. Karst – Since we started this blogging gig seven years ago (March […]
View ArticleOrphan drug developer Infant Bacterial Therapeutics gets $4.1 million
Clinical trials are three years away for this necrotising enterocolitis treatment.
View ArticleMorning Read: Is Martin Shkreli pharma’s version of the patent troll?
Also, the narrative shifts for FDA nominee Robert Califf, good news on Merck’s c. diff treatment, and here’s one part of Obamacare everyone hates.
View ArticleWhy drug-price regulation’s time has come
It’s not just noise. This is an issue that needs to be addressed.
View ArticleA new way to treat chronic cough got a big round of funding to move faster...
Patara Pharma now has a total of $33 million – including private investment and loans.
View ArticleReport: Orphan drugs cost 13.8 percent more per patient
The orphan drug industry is somewhat static in growth, but significantly outpaces the mass market drug industry, according to a new report from EvaluatePharma.
View ArticleClik here to view.
Orphan Drug Act’s role as an incentive to develop rare disease treatments
Before 1983 only 10 drugs had been approved to treat a rare disease, but as of November 2015 over 450 additional new orphan indications (both new drugs and secondary indications for previously approved...
View ArticleClik here to view.
Pharma companies routinely bend orphan drug rules
A Kaiser Health News investigation shows that the system intended to help desperate patients is being manipulated by drugmakers to maximize profits and to protect niche markets for medicines already...
View ArticleClik here to view.
Grassley opens probe into Orphan Drug Act abuses
In a statement, Grassley said the inquiry is “based on reporting from Kaiser Health News” and strong consumer concern about high drug prices.
View ArticleClik here to view.
Are pharma industry companies converting patients with orphan diseases into...
Behind-the-scenes partnerships between the pharmaceutical industry and advocacy groups may work against lowering the cost of high-priced drugs.
View Article
